Latiglutenase Treatment for Celiac Disease: Symptom and Quality of Life Improvement for Seropositive Patients on a Gluten-Free Diet.
| Autor: | Syage JA; ImmunogenX, Newport Beach, CA, United States., Green PHR; Celiac Disease Center, Columbia University, New York, NY, United States., Khosla C; Stanford University, Stanford, CA, United States., Adelman DC; Aimmune Therapeutics, Brisbane, CA, United States., Sealey-Voyksner JA; ImmunogenX, Newport Beach, CA, United States., Murray JA; Mayo Clinic, Rochester, MN, United States. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | GastroHep [GastroHep] 2019 Nov; Vol. 1 (6), pp. 293-301. Date of Electronic Publication: 2019 Oct 08. |
| DOI: | 10.1002/ygh2.371 |
| Abstrakt: | Background: Celiac disease (CD) is a widespread autoimmune disease triggered by dietary gluten that can lead to severe gastrointestinal symptoms. Because there is no available treatment other than a lifelong gluten-free diet, many patients continue to experience chronic symptoms. Aim: In this analysis we report on the efficacy of latiglutenase, an orally administered enzyme treatment, for improving multiple gluten-induced symptoms and consequent quality of life (QOL) due to inadvertent gluten consumption. Methods: This analysis is based on data from the CeliAction study of symptomatic patients (ALV003-1221; NCT01917630). Patients were treated with latiglutenase or placebo for 12 weeks and instructed to respond to a symptom diary daily and to multiple QOL questionnaires at weeks 0, 6, and 12 of the treatment periods as secondary endpoints. The results were stratified by serostatus. Results: 398 patients completed the 12-week CDSD study. In seropositive, but not seronegative, CD patients a statistically significant and dose-dependent improvement was seen in the severity and frequency of abdominal pain, bloating, tiredness, and constipation. In subjects receiving 900 mg latiglutenase, improvements (p-values) in the severity of these symptoms for week 12 were 58% (0.038), 44% (0.023), 21% (0.164), and 104% (0.049) respectively, relative to placebo-dosed subjects. The reduction in symptoms trended higher for more symptomatic patients. Similar results were observed for the QOL outcome measures. Conclusions: Although this study was not powered to definitively establish the benefit of latiglutenase in seropositive CD patients, such patients appear to show symptomatic and QOL benefit from using latiglutenase with meals. Competing Interests: Conflict of Interest Statement: JAS is a founder of and owns stock in ImmunogenX. JAM has received grant support from the National Institutes of Health, Alvine Pharmaceuticals, and Alba Therapeutics; receives ongoing support from Oberkotter Foundation and Broad Medical Research Program at CCFA; serves on the advisory board of ImmunogenX; was a consultant to GlaxoSmithKline (GSK), Genentech, and Glenmark Pharmaceuticals Ltd; and is a consultant to ImunnosanT, Institute for Protein Design (PvP Biologics), Takeda Pharmaceutical Company, Ltd., Innovate Biopharmaceuticals, Inc., and Intrexon. PHRG is an advisor to ImmusanT and ImmunogenX. CK is a director of Protagonist Pharmaceuticals and an advisor to Sitari Pharmaceuticals, and holds stock in both companies. JASV is a founder of and owns stock in ImmunogenX. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|